
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is showing strong revenue growth and volume expansion, boosted by its expanded sales force and new biomarker launches. The company's focus on revenue cycle management and cost control initiatives, along with the potential for increased payment from commercial payors, demonstrate its commitment to maintaining positive cash flow. With a growing pipeline of biopharma deals and continued improvements in ASPs, Exagen's strong financial performance is expected to continue.
Bears say
Exagen is a commercial-stage diagnostics company with a focus on autoimmune diseases, specifically SLE and RA. The company's reliance on one operating segment and majority of its revenue being derived from sales of testing products increases the risk of the company's operations. Additionally, the company's financials show a lack of consistent profitability, with net losses reported in recent years.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares